The Hippo pathway in cancer: YAP/TAZ and TEAD as therapeutic targets in cancer

R Cunningham, CG Hansen - Clinical Science, 2022 - portlandpress.com
Tumorigenesis is a highly complex process, involving many interrelated and cross-acting
signalling pathways. One such pathway that has garnered much attention in the field of …

Non-genetic adaptive resistance to KRASG12C inhibition: EMT is not the only culprit

W Ning, TM Marti, P Dorn, RW Peng - Frontiers in oncology, 2022 - frontiersin.org
Adaptions to therapeutic pressures exerted on cancer cells enable malignant progression of
the tumor, culminating in escape from programmed cell death and development of resistant …

Integrated analysis of cervical squamous cell carcinoma cohorts from three continents reveals conserved subtypes of prognostic significance

A Chakravarthy, I Reddin, S Henderson, C Dong… - Nature …, 2022 - nature.com
Human papillomavirus (HPV)-associated cervical cancer is a leading cause of cancer
deaths in women. Here we present an integrated multi-omic analysis of 643 cervical …

[HTML][HTML] Targeting histone deacetylase enhances the therapeutic effect of Erastin-induced ferroptosis in EGFR-activating mutant lung adenocarcinoma

T Zhang, B Sun, C Zhong, K Xu, Z Wang… - … lung cancer research, 2021 - ncbi.nlm.nih.gov
Background Intrinsic or acquired resistance to epidermal growth factor receptor-tyrosine
kinase inhibitors (EGFR-TKIs) is common, thus strategies for the management of EGFR-TKIs …

[HTML][HTML] Gene therapy for diffuse pleural mesotheliomas in preclinical models by concurrent expression of NF2 and SuperHippo

R Zhu, X Liu, X Zhang, Z Zhong, S Qi, R Jin, Y Gu… - Cell Reports …, 2024 - cell.com
Diffuse pleural mesothelioma (DPM) is a lethal cancer with a poor prognosis and limited
treatment options. The Hippo signaling pathway genes, such as NF2 and LATS1/2, are …

Tumor intrinsic and extrinsic functions of CD73 and the adenosine pathway in lung cancer

RR Kowash, EA Akbay - Frontiers in immunology, 2023 - frontiersin.org
The adenosine pathway is an exciting new target in the field of cancer immunotherapy.
CD73 is the main producer of extracellular adenosine. Non-small cell lung cancer (NSCLC) …

MEK1 drives oncogenic signaling and interacts with PARP1 for genomic and metabolic homeostasis in malignant pleural mesothelioma

H Yang, Y Gao, D Xu, K Xu, SQ Liang, Z Yang… - Cell death …, 2023 - nature.com
Malignant pleural mesothelioma (MPM) is a lethal malignancy etiologically caused by
asbestos exposure, for which there are few effective treatment options. Although asbestos …

Molecular alterations in malignant pleural mesothelioma: A hope for effective treatment by targeting YAP

F Dubois, C Bazille, J Levallet, E Maille, S Brosseau… - Targeted Oncology, 2022 - Springer
Malignant pleural mesothelioma is a rare and aggressive neoplasm, which has primarily
been attributed to the exposure to asbestos fibers (83% of cases); yet, despite a ban of using …

Mesothelioma malignancy and the microenvironment: molecular mechanisms

F Cersosimo, M Barbarino, S Lonardi, W Vermi… - Cancers, 2021 - mdpi.com
Simple Summary In the tumor microenvironment, interaction among tumor cells, immune
cells, stromal cells, and the extracellular matrix is vital to support pro-tumor mechanisms …

NF2: An underestimated player in cancer metabolic reprogramming and tumor immunity

D Xu, S Yin, Y Shu - npj Precision Oncology, 2024 - nature.com
Abstract Neurofibromatosis type 2 (NF2) is a tumor suppressor gene implicated in various
tumors, including mesothelioma, schwannomas, and meningioma. As a member of the ezrin …